Skip to main content

Table 3 Comparison of antimicrobial regimens in hospitalized elderly CAP patients with clinical failure and clinical success (n = 3011)

From: Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients

Regimen CF(n = 395) CS(n = 2616) p value
Consistent with guideline 115 (29.1) 1032 (39.4) <0.001
β-lactam 76 (19.2) 579 (22.1)  
Fluoroquinolone 22 (5.6) 368 (14.1)  
β-lactam + macrolide 6 (1.5) 74 (2.8)  
β-lactam + fluoroquinolone 22 (5.6) 11 (0.4)  
Undertreated by guideline 138 (34.9) 396 (15.1) <0.001
β-lactam 99 (25.1) 302 (11.5)  
β-lactam + macrolide 8 (2.0) 42 (1.6)  
Macrolide 1 (0.3) 18 (0.7)  
Fluoroquinolone +/− β-lactam/other 18 (4.6) 17 (0.6)  
Other combination 12 (3.0) 17 (0.6)  
Overtreated by guideline 142 (35.9) 1188 (45.4) <0.001
Antipseudomonal β-lactam 47 (11.9) 468 (17.9)  
Fluoroquinolone +β-lactam/ other 71 (18.0) 585 (22.4)  
Antipseudomonal β-lactam+ macrolide 6 (1.5) 45 (1.7)  
Antipseudomonal β-lactam + other 11 (2.8) 52 (2.0)  
Fluoroquinolone + macrolide 0 (0) 17 (0.6)  
β-lactam +quinolone+ other 5 (1.3) 11 (0.4)  
β-lactam +macrolide+ fluoroquinolone /other 2 (0.5) 10 (0.4)  
  1. Note: other = imidazoles, lincomycin, etracyclines, aminoglycoside, fosfomycin, glycopeptides and antifungal agents